In addition, a novel orally active, gut‐restricted drug named NX‐13 has been shown to activate mouse NLRX1 and alleviate disease severity in IBD mouse models, as well as increased OXPHOS, decreased differentiation into Th1 and Th17 subsets and decreased ROS and NF‐κB activation in naïve CD4+ T cells. The gene discussed is NLRX1; the disease is inflammatory bowel disease.